



24 February 2012

Market Announcement Office
Australian Securities Exchange
Level 6, 20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

NEW BUSINESS

The Group is pleased to announce that its wholly owned subsidiary Sys-Mac Automation Engineering Pte Ltd (Sys-Mac) has invested 80% into a new subsidiary, SAEdge Vision Systems Pte Ltd (SAEdge), focused on optic and vision system engineering. The total investment is S\$800,000.00 fully funded internally.

Optic and vision systems are employed for accurate inspection and measurement of high throughput production in a production line and are particularly suitable for fine and small components, which conventional systems may be unable to do. Vision systems are also used for alignment. The technology is synergistic with Sys-Mac's and our subsidiary Orion System Integration Pte Ltd's (Orion) businesses. SAEdge will fully complement and strengthen Sys-Mac's focus on automation business and complement Orion in developing and marketing its technology to its customers engaged in fine pitch flip chip assembly.

SAEdge has commenced business. While we do not expect any contribution in this financial year, we are, however, confident that SAEdge is able to contribute to the Group in the financial year 2013.

ASSOCIATE CURIQX SETS UP SUBSIDIARY IN USA

The Group wishes to announce that its 41% owned associate company, Curiox Biosystems Pte Ltd (Curiox) has set up a wholly owned subsidiary in San Francisco, USA. Curiox, USA will drive its technology into the USA and Europe and at the same time seek and establish alliances with partners to expand research and applications of its technology in these countries. The CEO who is an inventor of Curiox's technology will be based in this USA office.

Curiox's patented DropArray technology has been fully validated by one of the world's largest drug companies in USA and the biggest pharmaceutical company in Japan. The technology is perfected and has been presented to various international conferences. Full commercialisation is now being launched in the USA and Japan. Curiox's products are handled by 2 distributors in Japan. Validation of its technology by a leading European drug company is in process.

Curiox's DropArray technology is employed for drug discoveries. The technology is employed through the use of a wall-less micro-plate complemented with a dedicated washing machine. It has been validated to achieve an average of 50-60% savings in cost of disease markers, reagents and biologists' time apart from increased accuracy in drug discoveries as compared with methodology currently being employed.

The DropArray technology is patented and is exclusively licensed to Curiox in perpetuity from A*Star, Singapore government owned largest research institute. The CEO was previously a research scientist in A*Star.

The Group is confident that Curiox's gestation is almost over. We look forward to Curiox contributing to the Group in 2013.

Yours faithfully
ZICOM GROUP LIMITED



G L Sim
Chairman.

For personal use only